Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma

Riccardo Taulli, Claudio Scuoppo, Francesca Bersani, +8

Cancer Research

K252a inhibits the oncogenic properties of Met, the HGF receptor

Alessandro Morotti, Silvia Mila, Paolo Accornero, +2

Oncogene

Signal TransductionSignaling PathwayCell RegulationCell SignalingReceptor Tyrosine Kinase +7

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer

Simone Gastaldi, Francesco Sassi, Paolo Accornero, +10

Oncogene

Lineage PlasticityMammary Luminal ProgenitorsDevelopmental BiologyBreast OncologyMammary Gland +8

Control of domain swapping in bovine odorant-binding protein

Roberto Ramoni, Florence Vincent, Alison E. Ashcroft, +5

Biochemical Journal

Protein ChemistryProteinlipid InteractionProtein SecretionProtein FunctionProtein Assembly +10

Functional effect of mir-27b on myostatin expression: a relationship in piedmontese cattle with double-muscled phenotype

Silvia Miretti, Eugenio Martignani, Paolo Accornero, +1

BMC Genomics

Human Milk Protein Production in Xenografts of Genetically Engineered Bovine Mammary Epithelial Stem Cells

Eugenio Martignani, Peter Eirew, Paolo Accornero, +2

PLoS ONE

Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma

Lorella Maniscalco, Selina Iussich, Emanuela Morello, +9

The Veterinary Journal

Tumor BiologyCanine Appendicular OsteosarcomaPathologyMedicineRadiation Oncology +2

RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis

Riccardo Taulli, Paolo Accornero, Antonia Follenzi, +9

Cancer Gene Therapy

Tumor BiologyRnai TechnologyLentiviral DeliveryImmunologyTpr-met-mediated Tumorigenesis +7

Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma

Francesca Bersani, Riccardo Taulli, Paolo Accornero, +4

European Journal of Cancer

OncologyBortezomib-mediated Proteasome InhibitionMedicineAnti-cancer AgentCancer Treatment +5

Two mutations affecting conserved residues in the Met receptor operate via different mechanisms

Diego Maritano, Paolo Accornero, Neris Bonifaci, +1

Oncogene

Met Receptor OperateDifferent MechanismsSignal TransductionG Protein-coupled ReceptorFunctional Selectivity +6